Lung SBRT Motion Management (GCC 1619)
Real-time optical surface monitoring data will be acquired from 44 human patients with primary or metastatic lung lesions during and after their 4DCT scan (standard-of-care at our institution). A patient-specific 4D model will be developed using the raw 4DCT projections time-correlated with real-time surface monitoring. In addition, before delivering each dose fraction (3 - 5 for lung SBRT), we will acquire three 15s kV fluoroscopic image acquisitions, time-correlated with optical surface monitoring. The acquisitions will be distributed over three well-spaced beam angles, e.g., every 4th angle for a 12-field plan.
Checked against the public recordLast updated May 8, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Maryland, Baltimore
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Eligible disease(s)/stage(s) - Patients with primary or metastatic lung lesions to be treated using stereotactic body radiotherapy (SBRT) will be eligible for this study. 2. Allowable type and amount of prior therapy - Any types and amounts of prior therapy will be allowed for this study. 3. Age restriction and/or gender/ethnic restrictions - Patients must be greater than or equal to 18 years of age. There are no gender or ethnic restrictions. 4. Life expectancy restrictions - None. 5. ECOG or Karnofsky Performance Status - Karnofsky performance status of 50 or greater 6. Requirements for organ and marrow function - None. 7. Ability to understand and the willingness to sign a written informed consent document. 8. Tumor motion \> 5 mm, maximum GTV dimension \< 50 mm - per guidelines established by the AAPM Task Group 7612 and RTOG 0236.13 Exclusion Criteria: 1. Children (age \<18) 2. Women who are pregnant or trying to get pregnant 3. Pain in supine position 4. Karnofsky performance status \< 50
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ummc MsgccBaltimore, Maryland
- Upper Chesapeake HealthBel Air, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 8, 2024. Always confirm current availability with the study team.